(Health-NewsWire.Net, May 06, 2015 ) This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H1, 2015 Pipeline Review of “Alopecia” addiction with 29 market data tables and 15 figures, spread across 68 pages is available http://www.rnrmarketresearch.com/alopecia-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=308842 .
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Alopecia
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
More reports on Autoimmune Drugs :
Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.
Complete report is available at http://www.rnrmarketresearch.com/global-systemic-lupus-erythematosus-sle-drugs-market-2015-2019-market-report.html .
RnR Market Research
+ 1 888 391 5441